NCT06140875

Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Charite University, Berlin, Germany · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with glioblastoma

Detailed description

Charité Universitätsmedizin Berlin is currently the only German University Hospital with an available capacitive radiofrequency electromagnetic field treatment device. While there is retrospective data available regarding the assumed effectiveness and low toxicity profile of radiofrequency electromagnetic field treatment for glioblastoma in the palliative setting, there is only few prospective data available on the combined effect first-line chemoradiation and radiofrequency electromagnetic field treatment. The investigators aim to conduct a feasibility trial and plan to compare the results with data of a prospective trial with a comparable patient population.

Conditions

• Glioblastoma

Interventions

Type	Name	Description
DEVICE	Radiofrequency electromagnetic field treatment	Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz

Timeline

• Start date: 2023-11-15
• Primary completion: 2029-05-14
• Completion: 2029-05-14
• First posted: 2023-11-20
• Last updated: 2025-02-13

Locations

1 site across 1 country: Germany